Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 10/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176625 | 1.00 | NPC1 (0.43) | NPC1HTTCNR1CNR2P2RX7 | |
| SCHEMBL14538328 | 0.89 | NPC1 (0.36) | NPC1CNR1CNR2P2RX7RAB9A | |
| SCHEMBL300665 | 0.86 | MAPK1 (0.35) | NPC1HTTCNR1CNR2P2RX7 | |
| SCHEMBL300543 | 0.86 | MAPK1 (0.35) | NPC1HTTCNR1CNR2P2RX7 | |
| SCHEMBL176483 | 0.82 | CNR1 (0.56) | NPC1HTTCNR1CNR2 | |
| SCHEMBL176790 | 0.82 | CNR1 (0.56) | NPC1HTTCNR1CNR2 | |
| SCHEMBL176623 | 0.78 | NPC1 (0.46) | NPC1HTTCNR1CNR2 | |
| SCHEMBL176622 | 0.78 | NPC1 (0.46) | NPC1HTTCNR1CNR2 | |
| SCHEMBL300513 | 0.78 | NPC1 (0.46) | NPC1HTTCNR1CNR2RAB9A | |
| SCHEMBL4915235 | 0.78 | NPC1 (0.46) | NPC1HTTCNR1CNR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | NPC1 601/4885HTT 440/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.